A new report projecting the future of the drug market shows that new vaccines could shift the profit balance in the pancreatic cancer drug market. Some estimates place the market to more than double by 2016.
Decision Resources, one of the industry's leading research and advisory firms for pharmaceutical and healthcare issues, published a report with the findings staing that the emergence of cancer vaccines, including drugs from Pharmexa and Cell Genesys, will be the key factor driving the pancreatic cancer drug market to more than double by 2016
